A detailed history of Rf&L Wealth Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Rf&L Wealth Management, LLC holds 48,000 shares of RVNC stock, worth $123,359. This represents 0.18% of its overall portfolio holdings.

Number of Shares
48,000
Previous 48,000 -0.0%
Holding current value
$123,359
Previous $123 Million 101.95%
% of portfolio
0.18%
Previous 0.09%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$2.34 - $4.73 $35,100 - $70,950
15,000 Added 45.45%
48,000 $123 Million
Q4 2023

Feb 14, 2024

BUY
$5.81 - $11.2 $29,049 - $56,000
5,000 Added 17.86%
33,000 $290 Million
Q3 2023

Nov 02, 2023

BUY
$11.47 - $25.07 $91,760 - $200,560
8,000 Added 40.0%
28,000 $321 Million
Q1 2023

May 03, 2023

BUY
$18.36 - $35.27 $367,200 - $705,400
20,000 New
20,000 $644 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Rf&L Wealth Management, LLC Portfolio

Follow Rf&L Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rf&L Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rf&L Wealth Management, LLC with notifications on news.